Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 16 of 16 for “"Prostate-specific membrane antigen"”.
-
Biochemical and Molecular Characterization of the Prostate-Specific Membrane Antigen (PSMA)
<p>Prostate cancer is the most common malignancy and the second leading cause of cancer death in males in the United States. Additionally, the number of deaths attributed to prostate cancer is increasing at a rate of approximately 8% a year. Development of new diagnostic and therapy strategies are …
-
Prostate Specific Membrane Antigen (PSMA): Immunoassay Development and Characterization of Transcriptional Regulation
<p>Prostate cancer (PCA) is the most common cancer and the second leading cause of death among American men. The high mortality is greatly attributed to the lack of early detection tools and effective treatment for metastasis and relapses. Biomarkers that can discriminate benign from malignant …
-
Characterizing glucocorticoid receptor in metastatic castration resistant prostate cancer
… in the context of enzalutamide resistant prostate cancer cells. Enzalutamide is a drug that functions to dampen androgen receptor (AR) signaling, thus inhibiting cancer dependency on the receptor protein. Although the application of the drug reduces AR signaling in these cancer cells, an …
-
Evaluating the role of a 99mTc-HYNIC-PSMA SPECT scan following a negative bone scan in men with prostate cancer: a single-centre, retrospective cohort study
… high-risk and unfavourable intermediate-risk prostate cancer, who had a 99mTc-HYNIC-PSMA SPECT (technetium-99m hydrazine nicotinamide prostate-specific membrane antigen singlephoton emission computerised tomography) scan following a negative 99mTc-MDP (technetium-99m methylene diphosphonate) …
-
Discovery of PSMA-Specific Peptide Ligands and Development of A Noncovalent Method to Attach Chemical Moieties to siRNA
… of this dissertation is to discover PSMA (Prostate Specific Membrane Antigen)-specific peptide ligands using phage display and employ peptide nucleic acid as a complementary linker to attach chemical moieties to siRNA. In Chapters 1 and 2, we introduced and discussed the background of …
-
Chemoligand therapy for metastatic castration-resistant prostate cancer
… of patients with metastatic castration-resistant prostate cancer (mCRPC) has moderate to high nonphysiological levels of a transmembrane protein known as prostate-specific membrane antigen (PSMA) and creates opportunities for precision medicine approaches. Using PSMA as a mechanism of disease …
-
DUPA α-Amanitin Conjugates for Targeted Prostate Cancer Therapy - Optimization and Evaluation of In Vivo Potency
Prostate cancer remains the 4th most common cancer worldwide and the 2nd most common cancer in men. The Prostate Specific Membrane Antigen (PSMA) attracted a great attention as a target for the development of personalized therapeutics. Out of two PSMA targeted antibody-drug conjugates (ADCs) in …
-
α-Amanitin-based Small Format-Drug Conjugates for Prostate Cancer Therapy: Enabling Anti-Tumor Activity by Tuning Pharmacokinetic Properties
… treatment with seven approved products. High specific recognition of tumor-associated antigens provided by antibodies allows the preferential localization of the cytotoxic drug at the tumor site, reducing the systemic toxicity of conventional chemotherapy. While majority of the most advanced …
-
Synthesis and evaluation of novel non-viral gene delivery systems for prostate cancer targeting
Prostate cancer is the second most widespread cancer in men worldwide. Treatment choices are limited to prostatectomy, hormonal and radiotherapy that commonly have deleterious side effects and vary in their efficacy, depending on the stage of the disease. Among novel experimental strategies, gene …
-
Investigating couplet strategies incorporating 4 pillars of cancer therapy
… in dogs with urothelial carcinomas. In male dogs specifically, uroepithelial cancers include invasive urothelial carcinoma and prostate carcinoma. The inability to distinguish invasive urothelial carcinoma involving the prostate from prostate carcinoma results in indiscriminate clinical management …
-
Balancing Antitumor Efficacy and Safety Profile: α-Amanitin-Based Fc-Small Molecule Drug Conjugates for Targeted Prostate Cancer Therapy
The tumor-specific delivery of cytotoxic drugs through antibody-drug conjugates (ADCs) represents a breakthrough in cancer therapy. However, besides high manufacturing costs, the utility of therapeutic ADCs may be limited by their immunogenicity and poor penetration into solid tumors due to their …
-
Concurrent detection and isolation of cellular and molecular biomarkers
… beads conjugated with antibodies against a specific antigen are used to isolate both free molecules and whole cells overexpressing an antigen. The captured cells and molecules are quantitatively analyzed together on the same device surface using fluorescent microscopy. The system was first …
-
Therapeutic Effects and Targeted Delivery of Eupenifeldin in Castration-Resistant Prostate Cancer
Castration-resistant prostate cancer (CRPC) poses a major therapeutic challenge, as it often fails to respond to standard treatments such as taxane-based chemotherapies, androgen receptor pathway inhibitors, and radioligand-based approaches1–4. Despite these treatments, CRPC remains incurable, and …
-
Drug Delivery Strategies Using Light Sensitive Molecules
… proteins that are expressed on their plasma membrane. A select few of them such as Folic Acid Receptor (FAR) and PSMA (Prostate Specific Membrane Antigen) are overexpressed in malignant cells. In our new designs, we attached folic acid and urea based (DUPA) ligand, which were previously …
-
Peptide-Based Platform For Cancer Therapeutics And Drug Transportation Across Blood-Brain Barrier
Prostate cancer is the most common male malignancy and remains the second-leading cause of death due to cancer in American men. While surgery and radiation are effective in prostate cancer therapy at early stages, the majority of the patients ultimately relapse and develop advanced prostate cancer. …